Research graph
References from Tislelizumab‑induced psoriasis in a patient with hepatocellular carcinoma: A case report. Local targets link to admitted publications; unresolved targets remain external evidence.
The blockade of immune checkpoints in cancer immunotherapy
10.1038/nrc3239 · 2012 · External reference
Tislelizumab: First approval
10.1007/s40265-020-01286-z · 2020 · External reference
Tislelizumab in Chinese patients with advanced solid tumors: An open-label, non-comparative, phase 1/2 study
10.1136/jitc-2019-000437 · 2020 · External reference
Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: The RATIONALE-301 phase 3 randomized clinical trial
10.1001/jamaoncol.2023.4003 · 2023 · External reference
Immune-related adverse events of immune checkpoint inhibitors: A review
10.3389/fimmu.2023.1167975 · 2023 · External reference
Psoriasis
10.1016/s0140-6736(14)61909-7 · 2015 · External reference
Radiation-triggered psoriasiform rash with systemic dissemination after prolonged PD-1 inhibitor therapy: A case report
10.1097/md.0000000000045550 · 2025 · External reference
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.001 · 2022 · External reference
A review of phototherapy protocols for psoriasis treatment
10.1016/j.jaad.2009.12.054 · 2011 · External reference
Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers - IL-12, IL-18 and IL-23
10.1111/j.0906-6705.2004.00246.x · 2004 · External reference
Nutritional risk screening (NRS 2002): A new method based on an analysis of controlled clinical trials
10.1016/s0261-5614(02)00214-5 · 2003 · External reference
Toxicity and response criteria of the Eastern cooperative oncology group
10.1097/00000421-198212000-00014 · 1982 · External reference
A method for estimating the probability of dverse drug reactions
10.1038/clpt.1981.154 · 1981 · External reference
Cutaneous manifestations of diabetes mellitus: A review
10.1007/s40257-017-0275-z · 2017 · External reference
Insulin allergy: A diagnostic and therapeutic strategy based on a retrospective cohort and a case-control study
10.1007/s00125-022-05710-9 · 2022 · External reference
Evidence-Based management of hepatocellular carcinoma: Systematic review and meta-analysis of randomized controlled trials (2002-2020)
10.1053/j.gastro.2021.06.008 · 2021 · External reference
Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
10.1097/md.0000000000031183 · 2022 · External reference
Onset of psoriasis with immune checkpoint inhibitor therapy: A systematic review
10.1016/j.jaad.2023.09.070 · 2024 · External reference
Cutaneous immune-related adverse events from immune checkpoint inhibitors: A comprehensive systematic review of 15,340 patients
2025 · External reference
Misuse of the Naranjo Adverse Drug Reaction Probability Scale in toxicology
10.3109/15563650.2013.811588 · 2013 · External reference
Hepatitis C virus core protein triggers expansion and activation of CD4+CD25+ regulatory T cells in chronic hepatitis C patients
10.1038/cmi.2014.119 · 2014 · External reference
T-cell plasticity in inflammatory skin diseases-the good, the bad, and the chameleons
10.1111/ddg.12677 · 2015 · External reference
Immune checkpoint inhibitor-related dermatologic adverse events
10.1016/j.jaad.2020.03.132 · 2020 · External reference
Mucocutaneous adverse events to immune checkpoint inhibitors
10.3389/falgy.2023.1147513 · 2023 · External reference
Perspectives on psoriasiform adverse events from immune checkpoint inhibitors: lessons learned from our practice
10.3390/medicina60030373 · 2024 · External reference
Psoriasis induced by first-line pembrolizumab in metastatic non-small cell lung cancer: A case report
10.3892/ol.2023.13897 · 2023 · External reference
Toripalimab induces exacerbation of psoriasis in an esophageal cancer patient: A case report
10.3389/fonc.2025.1596818 · 2025 · External reference
Psoriasis caused by Camrelizumab in a patient with esophageal cancer: A case report
10.3389/fmed.2025.1647297 · 2025 · External reference
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
10.1136/jitc-2021-003066 · 2021 · External reference
Immune checkpoint inhibitor-associated cutaneous adverse events: mechanisms of occurrence
10.3390/ijms26010088 · 2024 · External reference
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
10.1007/s00262-004-0653-2 · 2005 · External reference
Advances on immune-related adverse events associated with immune checkpoint inhibitors
10.1007/s11684-019-0735-3 · 2021 · External reference
Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor-related skin adverse reactions (2024 edition)
10.3760/cma.j.cn112137-20240112-00091 · 2024 · External reference
NB-UVB irradiation attenuates inflammatory response in psoriasis
10.1111/dth.13626 · 2020 · External reference
Elucidating the NB-UVB mechanism by comparing transcriptome alteration on the edge and center of psoriatic plaques
10.1038/s41598-023-31610-y · 2023 · External reference
